OptimizeRx (OPRX) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenue grew 55% year-over-year to $29.2 million, with gross profit up 59% to $18.6 million, surpassing expectations and driven by DTC and DAAP sales.

• Adjusted EBITDA reached $5.8 million, up over $5 million year-over-year.

• Net income was $1.5 million, reversing a net loss of $4 million in Q2 2024.

• Non-GAAP net income reached $4.5 million, or $0.24 per diluted share, up from $0.3 million in Q2 2024.

• The company operates a single reporting segment focused on digital healthcare technology, with a "land and expand" strategy targeting enterprise-level engagements.

Financial highlights

• Gross margin improved to 63.8% from 62.2% year-over-year, driven by favorable product and channel mix.

• Operating expenses remained flat at $15.4 million despite significant revenue growth.

• Operating cash flow for H1 2025 was $8.4 million; quarter-end cash balance was $16.6 million.

• GAAP net income per share was $0.08 basic and diluted, compared to $(0.22) last year.

• Working capital at June 30, 2025, was $33.0 million; current ratio was 2.6.

Outlook and guidance

• 2025 revenue guidance increased to $104–$108 million; adjusted EBITDA to $14.5–$17.5 million.

• Management expects continued profitable growth and margin expansion through high-margin DAAP and subscription-based models.

• No expectation to access equity capital markets due to strong free cash flow and accelerated debt repayment.

• Funds from operations and existing cash are expected to be sufficient for the next 12 months; additional financing may be sought for acquisitions.

• Early 2026 indicators are promising; current consensus for 2026 revenue and adjusted EBITDA seen as reasonable.